PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.

Abstract Sublingual immunotherapy and subcutaneous immunotherapy are effective in seasonal allergic rhinitis. Three years of continuous treatment with subcutaneous immunotherapy and sublingual immunotherapy has been shown to improve symptoms for at least 2 years following discontinuation of treatment.
PMID
Related Publications

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.

Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study.

The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis.

300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.

Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title jama
Publication Year Start




PMID- 28196255
OWN - NLM
STAT- MEDLINE
DA  - 20170214
DCOM- 20170317
LR  - 20170317
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 317
IP  - 6
DP  - 2017 Feb 14
TI  - Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on
      Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to
      Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
PG  - 615-625
LID - 10.1001/jama.2016.21040 [doi]
AB  - Importance: Sublingual immunotherapy and subcutaneous immunotherapy are effective
      in seasonal allergic rhinitis. Three years of continuous treatment with
      subcutaneous immunotherapy and sublingual immunotherapy has been shown to improve
      symptoms for at least 2 years following discontinuation of treatment. Objective: 
      To assess whether 2 years of treatment with grass pollen sublingual
      immunotherapy, compared with placebo, provides improved nasal response to
      allergen challenge at 3-year follow-up. Design, Setting, and Participants: A
      randomized double-blind, placebo-controlled, 3-parallel-group study performed in 
      a single academic center, Imperial College London, of adult patients with
      moderate to severe seasonal allergic rhinitis (interfering with usual daily
      activities or sleep). First enrollment was March 2011, last follow-up was
      February 2015. Interventions: Thirty-six participants received 2 years of
      sublingual immunotherapy (daily tablets containing 15 microg of major allergen
      Phleum p 5 and monthly placebo injections), 36 received subcutaneous
      immunotherapy (monthly injections containing 20 microg of Phleum p 5 and daily
      placebo tablets) and 34 received matched double-placebo. Nasal allergen challenge
      was performed before treatment, at 1 and 2 years of treatment, and at 3 years (1 
      year after treatment discontinuation). Main Outcomes and Measures: Total nasal
      symptom scores (TNSS; range; 0 [best] to 12 [worst]) were recorded between 0 and 
      10 hours after challenge. The minimum clinically important difference for change 
      in TNSS within an individual is 1.08. The primary outcome was TNSS comparing
      sublingual immunotherapy vs placebo at year 3. Subcutaneous immunotherapy was
      included as a positive control. The study was not powered to compare sublingual
      immunotherapy with subcutaneous immunotherapy. Results: Among 106 randomized
      participants (mean age, 33.5 years; 34 women [32.1%]), 92 completed the study at 
      3 years. In the intent-to-treat population, mean TNSS score for the sublingual
      immunotherapy group was 6.36 (95% CI, 5.76 to 6.96) at pretreatment and 4.73 (95%
      CI, 3.97 to 5.48) at 3 years, and for the placebo group, the score was 6.06 (95% 
      CI, 5.23 to 6.88) at pretreatment and 4.81 (95% CI, 3.97 to 5.65) at 3 years. The
      between-group difference (adjusted for baseline) was -0.18 (95% CI, -1.25 to
      0.90; [P = .75]). Conclusions and Relevance: Among patients with moderate to
      severe seasonal allergic rhinitis, 2 years of sublingual grass pollen
      immunotherapy was not significantly different from placebo in improving the nasal
      response to allergen challenge at 3-year follow-up. Trial Registration:
      clinicaltrials.gov Identifier: NCT01335139; EudraCT Number: 2010-023536-16.
FAU - Scadding, Guy W
AU  - Scadding GW
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
FAU - Calderon, Moises A
AU  - Calderon MA
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
FAU - Shamji, Mohamed H
AU  - Shamji MH
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
FAU - Eifan, Aarif O
AU  - Eifan AO
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
FAU - Penagos, Martin
AU  - Penagos M
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
FAU - Dumitru, Florentina
AU  - Dumitru F
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
FAU - Sever, Michelle L
AU  - Sever ML
AD  - Rho Federal Systems Division, Chapel Hill, North Carolina.
FAU - Bahnson, Henry T
AU  - Bahnson HT
AD  - Rho Federal Systems Division, Chapel Hill, North Carolina3currently with the
      Immune Tolerance Network, Benaroya Research Institute, Seattle, Washington.
FAU - Lawson, Kaitie
AU  - Lawson K
AD  - Rho Federal Systems Division, Chapel Hill, North Carolina.
FAU - Harris, Kristina M
AU  - Harris KM
AD  - Immune Tolerance Network, Bethesda, Maryland.
FAU - Plough, Audrey G
AU  - Plough AG
AD  - Immune Tolerance Network, San Francisco, California.
FAU - Panza, Joy Laurienzo
AU  - Panza JL
AD  - National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
FAU - Qin, Tielin
AU  - Qin T
AD  - Immune Tolerance Network, Bethesda, Maryland.
FAU - Lim, Noha
AU  - Lim N
AD  - Immune Tolerance Network, Bethesda, Maryland.
FAU - Tchao, Nadia K
AU  - Tchao NK
AD  - Immune Tolerance Network, San Francisco, California7currently with the Department
      of Early Development Hematology/Oncology, Amgen, San Francisco, California.
FAU - Togias, Alkis
AU  - Togias A
AD  - National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
FAU - Durham, Stephen R
AU  - Durham SR
AD  - Imperial College, London, and Royal Brompton and Harefield Hospitals NHS
      Foundation Trust, London, United Kingdom.
CN  - Immune Tolerance Network GRASS Study Team
LA  - eng
SI  - EudraCT/2010-023536-16
SI  - ClinicalTrials.gov/NCT01335139
GR  - UM1 AI109565/AI/NIAID NIH HHS/United States
GR  - UM2 AI117870/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - JAMA
JT  - JAMA
JID - 7501160
RN  - 0 (Allergens)
SB  - AIM
SB  - IM
CIN - JAMA. 2017 Feb 14;317(6):591-593. PMID: 28196239
MH  - Adult
MH  - Allergens/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Intention to Treat Analysis
MH  - Male
MH  - Phleum/adverse effects/*immunology
MH  - Pollen/adverse effects/*immunology
MH  - Rhinitis, Allergic, Seasonal/ethnology/*therapy
MH  - Sublingual Immunotherapy/adverse effects/*methods
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2017/02/15 06:00
MHDA- 2017/03/18 06:00
CRDT- 2017/02/15 06:00
AID - 2601501 [pii]
AID - 10.1001/jama.2016.21040 [doi]
PST - ppublish
SO  - JAMA. 2017 Feb 14;317(6):615-625. doi: 10.1001/jama.2016.21040.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>